Company’s synthetic affinity reagents are antibody alternatives designed to advance the speed, safety, and efficiency of manufacturing at scale, making advanced therapies more accessible to patients. Investment led by Mercia Ventures, with Calculus Capital and Angel investors also participating. MIP Discovery, an innovative developer of non-biological affinity reagents designed to accelerate the development and production … Continued

Funding received from the Bill & Melinda Gates Foundation for rapid deployment of novel detection reagents to support mass scale testing in low to middle-income countries. Deployment of effective diagnostic testing is key to managing disease outbreaks at the regional or global level. The challenge is being able to design a diagnostic quickly, that can … Continued